Form 8-K - Current report:
SEC Accession No. 0001628280-21-006141
Filing Date
2021-03-30
Accepted
2021-03-30 17:09:44
Documents
14
Period of Report
2021-03-26
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K mrtx-20210326.htm   iXBRL 8-K 38945
  Complete submission text file 0001628280-21-006141.txt   180034

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrtx-20210326.xsd EX-101.SCH 2418
3 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT mrtx-20210326_cal.xml EX-101.CAL 710
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mrtx-20210326_def.xml EX-101.DEF 1647
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrtx-20210326_lab.xml EX-101.LAB 24275
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrtx-20210326_pre.xml EX-101.PRE 12646
7 EXTRACTED XBRL INSTANCE DOCUMENT mrtx-20210326_htm.xml XML 10523
Mailing Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

EIN.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35921 | Film No.: 21787673
SIC: 2834 Pharmaceutical Preparations